Minimal-/non-invasive and personalized diagnostic is regarded to be key for cancer screening, as well as other diseases. Not only because of recent advantages seen in the field of liquid biopsies that are typically minimal-/non-invasive, but additionally by its associated convenience for patients. Often it can be done with a small sample of the patient’s blood. Nevertheless, the patient’s acceptance is as needed as good sensitive and specificity of each used marker. Many promising markers are available, such as, RNA/DNA based or proteins, circulating tumor cells (CTCS) or extracellular vesicles (EVs). But are those novel markers better than established methodologies as stated in recommended guidelines? And if so, why are they not already in use?
This Research Topic aims to discuss and promote various minimal-/non-invasive methodologies, so called liquid biopsies, and associated markers. To summarize those existing, to discuss their benefits and weakness, their clinical performances as well as to discuss novel strategies, such as, how should the optimal liquid biopsy marker perform? Do we expect too much from such markers, meaning experimental markers are not making the cut? May such markers help us to tackle infectious diseases, cancer and other life-threatening conditions? Will they predict patient’s outcome and survivability? Do we identify other possible areas of application of various minimal-/non-invasive markers, for example, space exploration and supporting diagnosis under circumstances when resources are limited?
The aim of the current Research Topic is to cover promising, recent, and novel research trends in minimal-/non-invasive methodology field. Areas to be covered in this Research Topic may include, but are not limited to:
- Cancer
- Infectious diseases/pandemics
- Advanced methodologies
- Biomarker variants
- Strategies of implementation
Minimal-/non-invasive and personalized diagnostic is regarded to be key for cancer screening, as well as other diseases. Not only because of recent advantages seen in the field of liquid biopsies that are typically minimal-/non-invasive, but additionally by its associated convenience for patients. Often it can be done with a small sample of the patient’s blood. Nevertheless, the patient’s acceptance is as needed as good sensitive and specificity of each used marker. Many promising markers are available, such as, RNA/DNA based or proteins, circulating tumor cells (CTCS) or extracellular vesicles (EVs). But are those novel markers better than established methodologies as stated in recommended guidelines? And if so, why are they not already in use?
This Research Topic aims to discuss and promote various minimal-/non-invasive methodologies, so called liquid biopsies, and associated markers. To summarize those existing, to discuss their benefits and weakness, their clinical performances as well as to discuss novel strategies, such as, how should the optimal liquid biopsy marker perform? Do we expect too much from such markers, meaning experimental markers are not making the cut? May such markers help us to tackle infectious diseases, cancer and other life-threatening conditions? Will they predict patient’s outcome and survivability? Do we identify other possible areas of application of various minimal-/non-invasive markers, for example, space exploration and supporting diagnosis under circumstances when resources are limited?
The aim of the current Research Topic is to cover promising, recent, and novel research trends in minimal-/non-invasive methodology field. Areas to be covered in this Research Topic may include, but are not limited to:
- Cancer
- Infectious diseases/pandemics
- Advanced methodologies
- Biomarker variants
- Strategies of implementation
